Molecular Markers in the Immunocompromised host

REFERENCES

• Boeckh, M., Gooley, T.A., Myerson, D., Cun-ningham, T., Schoch, G. & Bowden, R.A.: Cy-tomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996;88,4063–71.
   Google Scholar
• Einsele, H., Ehninger, G., Hebart, H., Wittkowski, K.M., Schuler, U., Jahn, G., Mackes, P., Herter, M., Klingebiel, T., Löffler, J., Wagner, S. & Muller, C.A.: Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86,2815–20.
   Google Scholar
• Reusser, P., Einsele, H., Lee, J., Volin, L., Ro-vira, M., Engelhard, D., Finke, J., Cordonnier, C., Link, H. & Ljungman, P.: Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus in-fection after allogeneic stem cell transplanta-tion. Blood 2002;99,1159–1164.
   Google Scholar
• Gor, D., Sabin, C., Prentice, H.G., Vyas, N., Man, S. & Griffiths, P.D.: Longitudinal fluc-tuations in cytomegalovirus load in bone mar-row transplant patients: relationship between peak virus load, donor/recipient serostatus acute GVHD and CMV disease. Bone Marrow Transplantation 1998;21,597–605.
   Google Scholar
• Nichols, W.G., Corey, L., Gooley, T., Drew, W.L., Miner, R., Huang, M., Davis, C. & Boeckh, M.: Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplanta-tion: risk factors, correlation with DNA load, and outcomes. Blood 2001;97,867–74.
   Google Scholar
• Bowden, R., Cays, M., Schoch, G., Sayers, M., Slichter, S., Welk, K., Haake, R., McCullough, J., Weisdorf, D. & Miller, W.: Comparison of filtered blood (FB) to seronegative blood prod-ucts (SB) for prevention of cytomegalovirus (CMV) infection after marrow transplant. Blood 1995; 86,3598–3603.
   Google Scholar
• Prentice, H.G., Gluckman, E., Powles, R.L., Ljungman, P., Milpied, N., Fernandez Ranada, J.M., Mandelli, F., Kho, P., Kennedy, L. & Bell, A.R.: Impact of long-term acyclovir on cytomegalovirus infection and survival after al-logeneic bone marrow transplantation. Euro-pean Acyclovir for CMV Prophylaxis Study Group. Lancet 1994;343,749–53.
   Google Scholar
• Ljungman, P., De La Camara, R., Milpied, N., Volin, L., Russell, C.A., Webster, A. & Crisp, A.: A randomised study of valaciclovir as pro-phylaxis against CMV reactivation in alloge-neic bone marrow transplant recipients. Blood 2002; 99:3050–6.
   Google Scholar
• Goodrich, J.M., Bowden, R.A., Fisher, L., Kel-ler, C., Schoch, G. & Meyers, J.D.: Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993;118,173–8.
   Google Scholar
• Winston, D.J., Ho, W.G., Bartoni, K., Du Mond, C., Ebeling, D.F., Buhles, W.C. & Champlin, R.E.: Ganciclovir prophylaxis of cy-tomegalovirus infection and disease in alloge-neic bone marrow transplant recipients. Results of a placebo- controlled, double-blind trial. Ann Intern Med 1993;118,179–84.
   Google Scholar
• Bacigalupo, A., Tedone, E., Van Lint, M.T., Trespi, G., Lönngren, M., Sanna, M.A., Moro, F., Frassoni, F., Occhini, D. & Gualandi, F.: CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections. Bone Marrow Transplant 1994;13,783–8.
   Google Scholar
• Reusser, P., Gambertoglio, J.G., Lilleby, K. & Meyers, J.D.: Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients. J Infect Dis1992;166,473–9.
   Google Scholar
• Goodrich, J.M., Mori, M., Gleaves, C.A., Du Mond, C., Cays, M., Ebeling, D.F., Buhles, W.C., DeArmond, B. & Meyers, J.D.: Early treatment with ganciclovir to prevent cy-tomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991;325,1601–7.
   Google Scholar
• Von Muller L., Hampl W., Hinz J., Meisel H., Reip A., Engelmann E., Heilbronn R., Gartner B., Kramer 0., Einsele H., Hebart H., Ljubicic T., Löffler J., Mertens T.: High variability be-tween results of different in-house tests for cy-tomegalovirus (CMV) monitoring and a stan-dardized quantitative plasma CMV PCR assay. J Clin Microbiol. 2002;40: 2285–7.
   Google Scholar
• Gerna, G., Baldanti, F., Lilleri, D., Parea, M., Alessandrino, E., Pagani, A., Locatelli, F., Middeldorp, J. & Revello, M.G.: Human cy-tomegalovirus immediate-early mRNA detec-tion by nucleic acid sequence-based amplifica-tion as a new parameter for preemptive therapy in bone marrow transplant recipients. J Clin Microbiol 2000;38, 1845–53.
   Google Scholar
• Hebart, H.., Rudolph, T., Loeffler, J., Middel-dorp, J., Ljubicic, T., Jahn, G., Einsele, H.: Evaluation of the NucliSens CMV pp67 assay for detection and monitoring of human cy-tomegalovirus infection after allogeneic stem cell transplantation. Bone Marrow Transplant. 2002;30: 181–7.
   Google Scholar
• Hebart, H., Wuchter, P., Loeffler, J., Gscheidle, B., Hamprecht, K., Sinzger, C., Jahn, G., Dietz, K., Kanz, L. & Einsele, H..: Evaluation of the Murex CMV DNA Hybrid Capture assay (ver-sion 2.0) for early diagnosis of cytomegalovirus infection in recipients of an allogeneic stem cell transplant. Bone Marrow Transplant 2001;28,213–8.
   Google Scholar
• Grundy, J.E., Ehrnst, A., Einsele, H., Emery, VC., Hebart, H., Prentice, H.G., Ljungman, P.: A three-center European external quality con-trol study of PCR for detection of cytomega-lovirus DNA in blood. J Clin Microbiol. 1996;34:1166–70.
   Google Scholar
• Reusser, P., Einsele, H., Lee, J., Volin, L., Ro-vira, M., Engelhard, D., Finke, J., Cordonnier, C., Link, H. & Ljungman, P.: Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus in-fection after allogeneic stem cell transplanta-tion. Blood 2002;99,1159–1164.
   Google Scholar
• Bacigalupo, A., Bregante, S., Tedone, E., Isaza, A., Van Lint, M.T., Trespi, G., Occhini, D., Gualandi, F., Lamparelli, T. & Marmont, A.M.: Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation. Trans-plantation 1996;62,376–80.
   Google Scholar
• Ljungman, P., Deliliers, G.L., Platzbecker, U., Matthes-Martin, S., Bacigalupo, A., Einsele, H., Ullmann, J., Musso, M., Trenschel, R., Ri-baud, P., Bornhauser, M., Cesaro, S., Crooks, B., Dekker, A., Gratecos, N., Klingebiel, T., Tagliaferri, E., Ullmann, A.J., Wacker, P. & Cordonnier, C.: Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 2001;97,388–92.
   Google Scholar
• Einsele, H., Hebart, H., Kauffmann-Schneider, C., Sinzger, C., Jahn, G., Bader, P., et al.: Risk factors for treatment failures in patients receiv-ing PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant 2000; 25:757–63..
   Google Scholar
• Nguyen, Q., Champlin, R., Giralt, S., Rolston, K., Raad, I., Jacobson, K., et al. : Late cy-tomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients. Clin Infect Dis 1999;28:618–623.
   PubMed Web of Science ®Google Scholar
• Micallef, IN., Chhanabhai, M., Gascoyne, RD., Shepherd, JD., Fung, HC., Nantel, SH., Toze, CL., Klingemann, HG., Sutherland, HJ., Hogge, DE., Nevill, TJ., Le, A., Barnett, MJ. Lymphoproliferative disorders following al-logeneic bone marrow transplantation: the Vancouver experience. Bone Marrow Trans-plant. 1998;22:981–7.
   PubMed Web of Science ®Google Scholar
• Curtis, R.E., Travis, L.B., Rowlings, P.A., So-cie, G., Kingma, D.W., Banks, P.M., Jaffe, E.S., Sale, G.E., Horowitz, M.M., Witherspoon, R.P., Shriner, D.A., Weisdorf, D.J., Kolb, H. .J., Sullivan, K.M., Sobocinski, K.A., Gale, R.P., Hoover, R.N., Fraumeni, J.F Jr., Deeg, H. .J.: Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood. 1999;94,2208–16.
   Google Scholar
• Schafer, H., Berger, C., Aepinus, C., Hebart, H., Beck, R., Kaiserling, E., Kanz, L., Einsele, H., Knecht, H:. Molecular pathogenesis of Ep-stein-Barr virus associated posttransplant lym-phomas: new insights through latent membrane protein 1 fingerprinting. Transplantation. 2001;72,492–6.
   Google Scholar
• Kuehnle, I., Huls, M.H., Liu, Z., Semmelmann, M., Krance, R.A., Brenner, M.K., Rooney, C.M. & Heslop, H.E. CD20 monoclonal anti-body (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 2000;95,1502–5.
   PubMed Web of Science ®Google Scholar
• Papadopoulos, E.B., Ladanyi, M., Emanuel, D., Mackinnon, S., Boulad, F., Carabasi, M.H., Castro-Malaspina, H., Childs, B.H., Gillio, A.P., Small, T.N., Young, J.W., Kernan, N.A. & O'Reilly, R.J:. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lym-phoproliferative disorders after allogeneic bone marrow transplantation [see comments]. N Engl J Med 1994;330,1185–91.
   Google Scholar
• Gustafsson, A., Levitsky, V., Zou, J.Z., Frisan, T., Dalianis, T., Ljungman, P., Ringden, 0., Winiarski, J., Ernberg, I. & Masucci, M.G.: Ep-stein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop post-transplant lymphoproliferative disease: prophy-lactic infusion of EBV-specific cytotoxic T cells. Blood 2000;95,807–14.
   Google Scholar
• Limaye, A.P., Huang, M.L., Atienza, E.E., Fer-renberg J.M, Corey L: Detection of Epstein Barr virus DNA in sera from transplant recipi-ents with lymphoproliferative disorders. J Clin Microbiol 1999;37,1113–1116
   Google Scholar
• Gartner, B.C, Schafer, H, Marggraff, K, Eisele, G, Schafer, M, Dilloo, D, Roemer, K, Laws, H.J, Sester, M, Sester, U, Einsele, H, Mueller-Lantzsch, N.: Evaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor post-transplant lymphoproliferative disease. J Clin Microbiol. 2002;40,351–8.
   Google Scholar
• van Esser, J.W., van der Holt, B., Meijer, E., Niesters, HG., Trenschel, R., Thijsen, S.F., van Loon, A.M., Frassoni, F., Bacigalupo, A., Schaefer, U.W., Osterhaus, A.D., Gratama, J.W., Lowenberg, B., Verdonck, L.F., Cornelis-sen, J.J:. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (S CT) and quantitatively pre-dicts EBV-lymphoproliferative disease follow-ing T-cell-depleted SCT. Blood. 2001;98,972–8.
   Google Scholar
• Maertens, J., Van Eldere, J., Verhaegen, J., Verbeken, E., Verschakelen, J., Boogaerts, M.: Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in al-logeneic stem cell transplant recipients. J Infect Dis. 2002;186:1297–306.
   Google Scholar
• Einsele, H., Hebart, H., Roller, G., Loeffler, J., Rothenhoefer, I., Mueller C.A., et al.: Detection and identification of fungal pathogens in blood by using molecular probes.J Clin Microbiol 1997;35,1353 0 60.
   Google Scholar
• Loeffler, J., Kloepfer, K., Hebart, H., Najvar, L., Graybill, J.R., Kirkpatrick, W.R., Patterson, T.F., Dietz, K., Bialek, R., Einsele, H.: Poly-merase chain reaction detection of aspergillus DNA in experimental models of invasive as-pergillosis. J Infect Dis. 2002;185:1203–6.
   Google Scholar
• Hebart, H., Löffler, J., Meisner, C., Serey, F., Schmidt, D., Bohme, A., Martin, H., Engel, A., Bunje, D., Kern, W.V., Schumacher, U., Kanz, L., Einsele, H.: Early detection of aspergillus infection after allogeneic stem cell transplanta-tion by polymerase chain reaction screening. J Infect Dis. 2000;181:1713–9.
   Google Scholar
• Löffler, J., Henke, N., Hebart, H., Schmidt, D., Hagmeyer, L., Schumacher, U., Einsele, H.: Quantification of fungal DNA by using fluo-rescence resonance energy transfer and the light cyclier system. J Clin Microbiol 2000; 38:586–590.
   Google Scholar